TY - JOUR
T1 - Contribution of glucose to crystallization of phenytoin in injectable dosage form by dilution with infusion fluids
AU - Onuki, Yoshinori
AU - Hasegawa, Naoki
AU - Ikegami-Kawai, Mayumi
AU - Suematsu, Takako
AU - Sakurai, Satoshi
AU - Shirozu, Shunsuke
AU - Tsubuki, Masayoshi
AU - Obata, Yasuko
AU - Takayama, Kozo
N1 - Publisher Copyright:
© 2014 The Pharmaceutical Society of Japan.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - The crystallization of phenytoin occurring after its dilution with infusion fluid is a major concern in the clinical use of injectable phenytoin. To gain further understanding of the crystallization, this study assessed details of the involvement of glucose in this action. For sample preparation, phenytoin crystals were created by diluting the injectable phenytoin with infusion fluids with different glucose concentrations at different temperature, and then the characteristics of the crystallization (e.g., crystal size in the long direction, accumulated amount over 24 h, and crystallization rate constant) were measured. Results of the analysis of variance indicated that the glucose concentration and temperature had significant impacts on the crystallization. The mode of action of the glucose concentration was suggested to be different from that of the incubation temperature. This study also examined the molecular mobility of components (i.e., glucose, propylene glycol, phenytoin) in the admixtures using diffusion NMR techniques. The findings will provide valuable information for the clinical use of injectable phenytoin.
AB - The crystallization of phenytoin occurring after its dilution with infusion fluid is a major concern in the clinical use of injectable phenytoin. To gain further understanding of the crystallization, this study assessed details of the involvement of glucose in this action. For sample preparation, phenytoin crystals were created by diluting the injectable phenytoin with infusion fluids with different glucose concentrations at different temperature, and then the characteristics of the crystallization (e.g., crystal size in the long direction, accumulated amount over 24 h, and crystallization rate constant) were measured. Results of the analysis of variance indicated that the glucose concentration and temperature had significant impacts on the crystallization. The mode of action of the glucose concentration was suggested to be different from that of the incubation temperature. This study also examined the molecular mobility of components (i.e., glucose, propylene glycol, phenytoin) in the admixtures using diffusion NMR techniques. The findings will provide valuable information for the clinical use of injectable phenytoin.
KW - Crystallization characteristic
KW - Diffusion coefficient
KW - Glucose
KW - Infusion fluid
KW - Johnson-Mehl-Avrami model
KW - Phenytoin
UR - http://www.scopus.com/inward/record.url?scp=84908141617&partnerID=8YFLogxK
U2 - 10.1248/cpb.c14-00353
DO - 10.1248/cpb.c14-00353
M3 - 学術論文
C2 - 25273057
AN - SCOPUS:84908141617
SN - 0009-2363
VL - 62
SP - 989
EP - 993
JO - Chemical and Pharmaceutical Bulletin
JF - Chemical and Pharmaceutical Bulletin
IS - 10
ER -